N-(2-氨基乙基)-4-(三氟甲基)苯磺酰胺 | 917096-84-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氨基乙基)-4-(三氟甲基)苯磺酰胺
• 中文别名: N-氨基乙基苯磺酰胺
• 英文名称: N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide
• CAS: 917096-84-5
• 化学式: C₉H₁₁F₃N₂O₂S
• mdl: MFCD10000907
• 分子量: 268.26
• InChiKey: HOVKSPHQQLXZON-UHFFFAOYSA-N

物化性质

• 熔点：
  111-115°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2935009090
• WGK Germany：
  3

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : N-(2-Aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide
CAS-No. : 917096-84-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37 Wear suitable protective clothing and gloves.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C9H11F3N2O2S
Molecular Weight : 268,26 g/mol
Component Concentration
N-(2-Aminoethyl)-4-(trifluoromethyl)benzenesulfonamide
CAS-No. 917096-84-5 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 111 - 115 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,577
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)-4-(三氟甲基)苯磺酰胺 在 盐酸 、 水 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 160.0h， 生成 H₃DPASAm
  参考文献：
  名称：

  含磺酰胺基的Mn2 +配合物，具有pH响应弛豫性。

  摘要：

  我们含有本两个配体Ñ附接到乙基-4-（三氟甲基）苯磺酰胺基团或者是6,6' - （azanediylbis（亚甲基））吡啶二羧酸单元（H 3 DPASAm）或2,2' - （1， 4,7-三氮烷-1,4-二基）二乙酸大环平台（H 3 NO2ASAm）。这些配体经设计可在水溶液中与Mn 2+络合后提供pH依赖性弛豫响应。配体的质子化常数和Mn 2+络合物的稳定性常数是通过分光光度法补充的电位滴定法测定的。配体的磺酰胺基团的去质子化的特征在于log K i的质子化常数对于DPASAm 3–和HNO2ASAm 2–，H分别为10.36和10.59 。由于带负电的磺酰胺基团与金属离子的配位，在Mn 2+存在下，这些值急剧下降至log K i H = 6.43和5.42 。[Mn（DPASAm）] -中较高的log K i H值与七配位络合物的形成有关，而[Mn（NO2ASAm）] -中金属离子为六配位。Na

  DOI：

  10.1021/acs.inorgchem.0c02098
• 作为产物：
  描述：

  在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 N-(2-氨基乙基)-4-(三氟甲基)苯磺酰胺
  参考文献：
  名称：

  具有 V600EBRAF 抑制作用的新型 4-(1H-苯并[d]咪唑-1-基)嘧啶-2-胺连接的磺酰胺衍生物的设计、合成和抗癌特性

  摘要：

  根据成熟的 V600EBRAF 抑制剂的结构，设计并合成了一系列新的 4-(1 H- benzo[ d ]imidazol-1-yl)pyrimidin-2-amine 连接的磺酰胺衍生物12a-n。末端磺酰胺部分通过乙胺或丙胺桥连接到嘧啶环。设计的系列在固定浓度 (1 µM) 下针对 V600EBRAF 进行测试，发现12e、12i和12l在所有目标化合物中表现出最强的抑制活性，12l的 IC 50最低，为 0.49 µM。他们在 NCI 60 癌细胞系上进一步筛选以揭示12e显示出对多种癌细胞系的最显着的生长抑制。因此，进行了12e 的细胞周期分析以研究对细胞周期进程的影响。最后，进行虚拟对接研究以深入了解 vemurafenib、12i、12e和12l的合理结合模式。

  DOI：

  10.3390/ijms221910491
• 作为试剂：
  描述：

  2-甲基戊醛 在 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 辛醇 、 N-(2-氨基乙基)-4-(三氟甲基)苯磺酰胺 、 sodium formate 作用下， 反应 4.0h， 生成 2-甲基-1-戊醇
  参考文献：
  名称：

  在水和空气中：用铱催化剂对醛进行快速且高度化学选择性的转移氢化。

  摘要：

  DOI：

  10.1002/anie.200602122

文献信息

• Iridium-catalyzed highly efficient chemoselective reduction of aldehydes in water using formic acid as the hydrogen source
  作者：Zhanhui Yang、Zhongpeng Zhu、Renshi Luo、Xiang Qiu、Ji-tian Liu、Jing-Kui Yang、Weiping Tang

  DOI：10.1039/c7gc01289f

  日期：——

  A water-soluble highly efficient iridium catalyst is developed for the chemoselective reduction of aldehydes to alcohols in water. The reduction uses formic acid as the traceless reducing agent and water as a solvent. It can be carried out in air without the need for inert atmosphere protection. The products can be purified by simple extraction without any column chromatography. The catalyst loading

  开发了一种水溶性高效铱催化剂，用于将水中的醛化学选择性还原为醇。还原使用甲酸作为无痕还原剂，并使用水作为溶剂。它可以在空气中进行，而无需惰性气体保护。可以通过简单的萃取来纯化产物，而无需任何柱色谱法。催化剂负载量可以低至0.005mol％，并且转换频率（TOF）高至73800mol mol -1 h -1。各种各样的官能团，例如富电子或不足的（杂）芳烃和烯烃，烷氧基，卤素，酚，酮，酯，羧酸，氰基和硝基，都具有良好的耐受性，这表明其具有出色的化学选择性。
• Design, synthesis,<i>in vitro</i>anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety
  作者：Mohammed S. Abdel-Maksoud、Mohammed I. El-Gamal、Mahmoud M. Gamal El-Din、Chang Hyun Oh

  DOI：10.1080/14756366.2018.1530225

  日期：2019.1.1

  Abstract The present work describes the design and synthesis of a novel series of 1,3-diaryl-4-sulfonamidoarylpyrazole derivatives 1a–q and 2a–q and their in vitro biological activities. The target compounds were evaluated for antiproliferative activity against NCI-60 cell line panel. Compounds 1c, 1g, 1k–m, 1o, 2g, 2h, 2k–m, 2o, and 2q showed the highest mean inhibition percentages at 10 µM single-dose

  抽象的 目前的工作描述了一系列新型的1,3-二芳基-4-磺酰胺基芳基吡唑衍生物1a-q和2a-q的设计和合成及其体外生物学活性。评价目标化合物对NCI-60细胞系的抗增殖活性。化合物1c，1g，1k–m，1o，2g，2h，2k–m，2o和2q在10 µM单剂量试验中显示出最高的平均抑制百分比，并被选择以5剂量模式进行试验。在60个细胞系中确定了最有效的化合物的IC 50。化合物2l对具有IC 50的不同细胞系表现出最强的活性针对A498肾癌细胞系的0.33 µM。在一组20种激酶中测试了化合物21，以确定其分子靶标，并定义了其对最敏感激酶的IC 50值。还研究了化合物2l的体外稳定性和体内药代动力学特征。
• Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages
  作者：Mohammed S. Abdel-Maksoud、Mohammed I. El-Gamal、Mahmoud M. Gamal El-Din、Yunji Choi、Jungseung Choi、Ji-Sun Shin、Shin-Young Kang、Kyung Ho Yoo、Kyung-Tae Lee、Daejin Baek、Chang-Hyun Oh

  DOI：10.3390/molecules23102556

  日期：——

  This article describes the design, synthesis, and in vitro anti-inflammatory screening of new triarylpyrazole derivatives. A total of 34 new compounds were synthesized containing a terminal arylsulfonamide moiety and a different linker between the sulfonamide and pyridine ring at position 4 of the pyrazole ring. All the target compounds were tested for both cytotoxicity and nitric oxide (NO) production

  本文介绍了新型三芳基吡唑衍生物的设计、合成和体外抗炎筛选。总共合成了 34 种新化合物，它们包含末端芳基磺酰胺部分和磺酰胺和吡唑环 4 位吡啶环之间的不同接头。测试了所有目标化合物在脂多糖 (LPS) 诱导的 RAW 264.7 巨噬细胞中的细胞毒性和一氧化氮 (NO) 产生抑制。化合物 1b、1d、1g、2a 和 2c 显示出最高的 NO 抑制百分比和最低的细胞毒性作用。测试了最有效的衍生物在 LPS 诱导的 RAW 264.7 巨噬细胞中抑制前列腺素 E2 (PGE2) 的能力。确定了对一氧化氮抑制、PGE2 抑制和细胞活力的 IC50。此外，1b、1d、1g、2a、
• Half-sandwich rhodium(III) transfer hydrogenation catalysts: Reduction of NAD+ and pyruvate, and antiproliferative activity
  作者：Joan J. Soldevila-Barreda、Abraha Habtemariam、Isolda Romero-Canelón、Peter J. Sadler

  DOI：10.1016/j.jinorgbio.2015.10.008

  日期：2015.12

  were determined to be ca. 8–10. Complexes 1–9 also catalysed the reduction of pyruvate to lactate using formate as the hydride donor. The efficiency of the transfer hydrogenation reactions was highly dependent on the nature of the chelating ligand and the Cpx ring. Competition reactions between NAD+ and pyruvate for reduction by formate catalysed by 4 showed a preference for reduction of NAD+. The

  有机金属配合物具有充当催化药物的潜力。我们在这里研究通式 [(Cp x )Rh( N , N ')(Cl)] 的Rh(III) 配合物，其中N , N ' 是乙二胺 (en), 2,2'-联吡啶 (bpy), 1 ,10-菲咯啉 (phen) 或N- (2-氨基乙基)-4-(三氟甲基)苯磺酰胺 (TfEn)，Cp x是五甲基环戊二烯基 (Cp*)、1-苯基-2,3,4,5-四甲基环戊二烯基 ( Cp xPh ) 或 1-联苯-2,3,4,5-四甲基环戊二烯基 (Cp xPhPh )。这些复合物可以减少 NAD +在生物学相关条件下，使用甲酸盐作为氢化物来源将 NADH 转化为 NADH。催化活性在的顺序减小Ñ，Ñ -chelated配体联吡啶>苯>烯再用Cp *作为η 5端供体。随着延伸到 Cp X环，en 复合物 ( 1-3 ) 变得更加活跃，而 phen ( 7-9 ) 和 bpy (
• Discovery of New Imidazo[2,1-<i>b</i>]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising <i>In Vitro</i> and <i>In Vivo</i> Anti-melanoma Activity
  作者：Mohammed S. Abdel-Maksoud、Mohammed I. El-Gamal、Bong S. Lee、Mahmoud M. Gamal El-Din、Hong R. Jeon、Dow Kwon、Usama M. Ammar、Karim I. Mersal、Eslam M. H. Ali、Kyung-Tae Lee、Kyung Ho Yoo、Dong Keun Han、Jae Kyun Lee、Garam Kim、Hong Seok Choi、Young Jik Kwon、Kwan Hyi Lee、Chang Hyun Oh

  DOI：10.1021/acs.jmedchem.1c00230

  日期：2021.5.27

  obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure–activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The

  BRAF是MAPK级联反应的重要组成部分。BRAF，特别是V600E的突变会导致MAPK途径过度活化和细胞生长不受控制。对突变的BRAF的选择性抑制剂的抗性是治疗许多癌症类型的主要障碍。在这项工作中，合成了一系列具有末端磺酰胺部分的新的（咪唑并[2,1 - b ]噻唑-5-基）嘧啶衍生物。研究了新系列的Pan-RAF抑制作用，并讨论了结构-活性关系。测试了目标化合物对NCI-60细胞系的抗增殖活性。对最具活性的化合物进行了进一步测试，以获得针对癌细胞的IC 50值。化合物27c末端开链磺酰胺和带有环状磺酰胺部分的38a在酶法和细胞分析中显示出最高的活性，并且两种化合物都能够抑制MEK和ERK的磷酸化。选择化合物38a以测试其针对黑素瘤的体内活性。报告了细胞和动物活动。